PLAZOMICIN SULFATE

Search structure
Trade Names:
Synonyms:
Status: Approved (2018)
Entry Type: Small molecule
Molecule Category: Salt
UNII: A78L6MT746
Parent Compound: PLAZOMICIN

Structure
InChI Key SFTBRKHJMASSAP-BGJNVEJLSA-N
Smile CN[C@@H]1[C@@H](O)[C@@H](O[C@@H]2[C@@H](O)[C@H](O[C@H]3OC(CNCCO)=CC[C@H]3N)[C@@H](N)C[C@H]2NC(=O)[C@@H](O)CCN)OC[C@]1(C)O.O=S(=O)(O)O
InChI
InChI=1S/C25H48N6O10.H2O4S/c1-25(37)11-38-24(18(35)21(25)29-2)41-20-15(31-22(36)16(33)5-6-26)9-14(28)19(17(20)34)40-23-13(27)4-3-12(39-23)10-30-7-8-32;1-5(2,3)4/h3,13-21,23-24,29-30,32-35,37H,4-11,26-28H2,1-2H3,(H,31,36);(H2,1,2,3,4)/t13-,14+,15-,16+,17+,18-,19-,20+,21-,23-,24-,25+;/m1./s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C25H50N6O14S
Molecular Weight 690.77
AlogP -5.36
Hydrogen Bond Acceptor 15.0
Hydrogen Bond Donor 11.0
Number of Rotational Bond 13.0
Polar Surface Area 269.29
Molecular species BASE
Aromatic Rings 0.0
Heavy Atoms 41.0

Pharmacology

Action Mechanism of Action Reference
INHIBITOR Bacterial 70S ribosome inhibitor FDA

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Urinary Tract Infections 4 D014552 FDA
Pyelonephritis 4 D011704 FDA

Related Entries

Scaffolds

Parent

Adverse Reactions

SOC By Demographic Distribution
System Organ Classification (SOC)
Relative Frequency (%)
Gastrointestinal disorders
14.29
Investigations
14.29
Nervous system disorders
14.29
Injury, poisoning and procedural complications
12.24
Ear and labyrinth disorders
10.2
Metabolism and nutrition disorders
10.2
General disorders and administration site conditions
6.12
Renal and urinary disorders
6.12
Cardiac disorders
4.08
Vascular disorders
4.08
Respiratory, thoracic and mediastinal disorders
2.04
Skin and subcutaneous tissue disorders
2.04

Cross References

Resources Reference
ChEMBL CHEMBL2364623
EPA CompTox DTXSID60160452
FDA SRS A78L6MT746
PubChem 71515458
CONTENTS